JP2007538008A5 - - Google Patents

Download PDF

Info

Publication number
JP2007538008A5
JP2007538008A5 JP2007510880A JP2007510880A JP2007538008A5 JP 2007538008 A5 JP2007538008 A5 JP 2007538008A5 JP 2007510880 A JP2007510880 A JP 2007510880A JP 2007510880 A JP2007510880 A JP 2007510880A JP 2007538008 A5 JP2007538008 A5 JP 2007538008A5
Authority
JP
Japan
Prior art keywords
matrix
methadone
formulation
styrene
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007510880A
Other languages
English (en)
Japanese (ja)
Other versions
JP5250257B2 (ja
JP2007538008A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/014240 external-priority patent/WO2005110381A1/en
Publication of JP2007538008A publication Critical patent/JP2007538008A/ja
Publication of JP2007538008A5 publication Critical patent/JP2007538008A5/ja
Application granted granted Critical
Publication of JP5250257B2 publication Critical patent/JP5250257B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007510880A 2004-04-29 2005-04-26 メサドン局所組成物およびその使用方法 Expired - Fee Related JP5250257B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56668604P 2004-04-29 2004-04-29
US60/566,686 2004-04-29
PCT/US2005/014240 WO2005110381A1 (en) 2004-04-29 2005-04-26 Topical methadone compositions and methods for using the same

Publications (3)

Publication Number Publication Date
JP2007538008A JP2007538008A (ja) 2007-12-27
JP2007538008A5 true JP2007538008A5 (enExample) 2008-04-17
JP5250257B2 JP5250257B2 (ja) 2013-07-31

Family

ID=35393974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007510880A Expired - Fee Related JP5250257B2 (ja) 2004-04-29 2005-04-26 メサドン局所組成物およびその使用方法

Country Status (21)

Country Link
US (1) US20050244486A1 (enExample)
EP (1) EP1740162A4 (enExample)
JP (1) JP5250257B2 (enExample)
KR (1) KR20070007850A (enExample)
CN (1) CN1976689A (enExample)
AR (1) AR048878A1 (enExample)
AU (2) AU2005244214B2 (enExample)
BR (1) BRPI0510428A (enExample)
CA (1) CA2563489C (enExample)
CR (1) CR8722A (enExample)
EA (1) EA011423B1 (enExample)
IL (1) IL178661A0 (enExample)
ME (1) MEP25008A (enExample)
MX (1) MXPA06012563A (enExample)
NO (1) NO20065455L (enExample)
NZ (1) NZ550963A (enExample)
RS (1) RS20060605A (enExample)
TW (1) TW200605870A (enExample)
UA (1) UA88464C2 (enExample)
WO (1) WO2005110381A1 (enExample)
ZA (1) ZA200608923B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2499067T3 (es) * 2005-10-13 2014-09-26 Nitto Denko Corporation Preparación transdérmica de nicotina y método de producción de la misma
US20080220062A1 (en) * 2006-10-23 2008-09-11 Psivida, Inc. Sustained release of agents for localized pain management
JP5704801B2 (ja) * 2008-08-21 2015-04-22 ニプロパッチ株式会社 粘着性組成物及び経皮吸収型製剤
GB2481728B (en) * 2010-06-30 2012-05-23 Londonpharma Ltd Formulations and delivery devices for the sublingual administration of opioids
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
SG11201407300VA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013175357A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (zh) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
US20240068023A1 (en) * 2021-01-14 2024-02-29 The Trustees Of Indiana University Methods to predict effects of perioperative administration of methadone to optimize pain relief and avoid adverse effects

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
ATE107517T1 (de) * 1989-05-25 1994-07-15 Takeda Chemical Industries Ltd Transdermales therapeutisches mittel.
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5883115A (en) * 1992-11-09 1999-03-16 Pharmetrix Division Technical Chemicals & Products, Inc. Transdermal delivery of the eutomer of a chiral drug
AU5551394A (en) * 1992-11-09 1994-06-08 Pharmetrix Corporation Combined analgesic delivery methods for pain management
US5589480A (en) * 1994-08-17 1996-12-31 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5947921A (en) * 1995-12-18 1999-09-07 Massachusetts Institute Of Technology Chemical and physical enhancers and ultrasound for transdermal drug delivery
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
DE19642043A1 (de) * 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
US6787149B1 (en) * 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
NZ504108A (en) * 1997-09-26 2002-06-28 Noven Pharma Bioadhesive compositions comprising a polyvinylpyrrolidone polymer and methods for topical administration of active agents
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
GB9804885D0 (en) * 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
DE19850517B4 (de) * 1998-11-03 2004-02-12 Lts Lohmann Therapie-Systeme Ag Verwendung eines wirkstoffhaltigen transdermalen therapeutischen Systems in einer Kombinationsbehandlung mit und ohne Ultraschall
GB9828480D0 (en) * 1998-12-24 1999-02-17 Dermatech Limited Transdermal drug delivery system
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2001052823A2 (en) * 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6586478B2 (en) * 2000-02-22 2003-07-01 Cellegy Canada Methods and compositions for improving sleep
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
ATE364561T1 (de) * 2001-10-22 2007-07-15 3M Innovative Properties Co Verpackung für transdermale/transmucosale pflaster
US6713470B2 (en) * 2002-01-22 2004-03-30 Ml Laboratories Plc Method of treatment

Similar Documents

Publication Publication Date Title
JP2007538008A5 (enExample)
DE602004011374D1 (de) Transdermale pharmazeutische zusammensetzung
WO2004078122A3 (en) Invisible patch for active agnet controlled delivery
WO2007066149A3 (en) Topical pharmaceutical compositions
JP2019537460A (ja) 有益物の局所送達のためのキット及び方法
PT957900E (pt) Composicoes e metodos para aplicacao topica de agentes terapeuticos
TW201043270A (en) Methods of administration of a dermatological agent to a subject
WO2011029948A3 (de) Transdermales therapeutisches system zur verabreichung von fentanyl oder einem analogstoff davon
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
JP2009534306A5 (enExample)
JP2005508963A5 (enExample)
US20050181028A1 (en) Topical composition and method for treating occlusive wounds
RU2007101538A (ru) Применение фармацевтической композиции, содержащей кальцитриол и пропионат клобетазола, для лечения псориаза
JP2009522207A5 (enExample)
WO2006088945A3 (en) Granulysin peptides and methods of use thereof
ES2391409T3 (es) Composición antifúngica
WO2006138571A3 (en) Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance
US12419829B2 (en) Topical product hands-free applicator drug delivery system and methods of making and using the same
US8367683B2 (en) Composition and method for treatment of warts
JPH01230514A (ja) エアゾール型外用貼付剤
JPH05245172A (ja) 長時間密封治療システム
EP3173066A1 (en) Plaster comprising antiedematous substances for the treatment of bruising and injury
CA2515259A1 (en) Use of acetylsalicylic acid for the treatment of hemorrhoidal disease
EP1758922B8 (en) Peptide substance restoring function of respiratory organs